Skip to main content
. Author manuscript; available in PMC: 2016 Mar 1.
Published in final edited form as: Anticancer Drugs. 2015 Mar;26(3):293–300. doi: 10.1097/CAD.0000000000000197

Figure 1.

Figure 1

A. MS-PCR analysis depicts the methylation status of the MGMT promoter in A172, U251, BT325 and U87-MG glioma cells. Methylated DNA was only observed in U87-MG cell line. MGMT unmethylated: 93 bp; MGMT methylated: 8l bp; U: unmethylated; M: methylated; PM: Positive control of methylated PCR reaction; PU: Positive control of unmethylated PCR reaction; N: Negative control; MM: molecular marker. B. Chemotherapeutic effect of temozolomide (TMZ) on cell viability of human glioma cell lines U87-MG, U251, A172 and BT325. Glioma cell lines were treated with TMZ at 0.4, 4, 40 μM, or vehicle controls (0.1% DMSO), and the cell viability was determined by CCK-8 assay. Depicted are mean ± S.E.M, n=10, *p<0.05 vs vehicle control.